应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09926 康方生物
休市中 07-26 16:08:20
40.650
+1.700
+4.36%
最高
40.800
最低
39.400
成交量
225.33万
今开
39.800
昨收
38.950
日振幅
3.59%
总市值
351.97亿
流通市值
351.97亿
总股本
8.66亿
成交额
9,077万
换手率
0.26%
流通股本
8.66亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
康方生物午后涨超3% 此前获华福证券给予“买入”评级
新浪港股 · 07-26 13:07
康方生物午后涨超3% 此前获华福证券给予“买入”评级
港股异动 | 康方生物(09926)现涨超3% 机构称AK112出海成功确定性逐步提升 公司当前市值被严重低估
智通财经 · 07-26 11:51
港股异动 | 康方生物(09926)现涨超3% 机构称AK112出海成功确定性逐步提升 公司当前市值被严重低估
康方生物委任首席财务官
北京商报 · 07-22
康方生物委任首席财务官
《大行》中金最新海外中资股策略首选组合(表)
阿斯达克财经 · 07-22
《大行》中金最新海外中资股策略首选组合(表)
康方生物(09926)：王秉中博士获委任为公司新任领导
和讯网 · 07-22
康方生物(09926)：王秉中博士获委任为公司新任领导
康方生物(09926)：王秉中获委任为公司首席财务官
智通财经 · 07-22
康方生物(09926)：王秉中获委任为公司首席财务官
康方生物(09926.HK)委任首席财务官
阿斯达克财经 · 07-22
康方生物(09926.HK)委任首席财务官
中欧医疗健康股票仓位升至三年最高 葛兰二季度十大重仓股出炉
澎湃新闻 · 07-19
中欧医疗健康股票仓位升至三年最高 葛兰二季度十大重仓股出炉
南向资金7月18日净买入康方生物49.10万股 连续7日增持
自选股智能写手 · 07-19
南向资金7月18日净买入康方生物49.10万股 连续7日增持
南向资金7月16日净买入康方生物8.69万股 连续5日增持
自选股智能写手 · 07-17
南向资金7月16日净买入康方生物8.69万股 连续5日增持
康方生物早盘涨近4% 华福证券首次覆盖给予“买入”评级
新浪港股 · 07-16
康方生物早盘涨近4% 华福证券首次覆盖给予“买入”评级
港股异动 | 康方生物(09926)涨超5% 卡度尼利一线治疗晚期宫颈癌III期研究达PFS和OS双主要终点
智通财经 · 07-16
港股异动 | 康方生物(09926)涨超5% 卡度尼利一线治疗晚期宫颈癌III期研究达PFS和OS双主要终点
康方生物(09926)上涨5.06%，报40.5元/股
金融界 · 07-16
康方生物(09926)上涨5.06%，报40.5元/股
康方生物盘中异动 早盘急速拉升5.06%报40.501港元
自选股智能写手 · 07-16
康方生物盘中异动 早盘急速拉升5.06%报40.501港元
康方生物(09926)股价上升5.058%，现价港币$40.5
阿斯达克财经 · 07-16
康方生物(09926)股价上升5.058%，现价港币$40.5
《大行》野村降康方生物(09926.HK)目标价至46.04元 下调今明两年收入预测
阿斯达克财经 · 07-16
《大行》野村降康方生物(09926.HK)目标价至46.04元 下调今明两年收入预测
南向资金7月12日净买入康方生物77.05万股 连续3日增持
自选股智能写手 · 07-15
南向资金7月12日净买入康方生物77.05万股 连续3日增持
康方公司核心产品的估值预估及其在国内市场的销售额预测
调研三人行 · 07-15
康方公司核心产品的估值预估及其在国内市场的销售额预测
港股异动 | 康方生物(09926)现涨近5% 依沃西单抗最大的不确定性已落地 有望后续在海外上市
智通财经网 · 07-12
港股异动 | 康方生物(09926)现涨近5% 依沃西单抗最大的不确定性已落地 有望后续在海外上市
康方生物盘中异动 早盘股价大涨5.09%
自选股智能写手 · 07-12
康方生物盘中异动 早盘股价大涨5.09%
加载更多
公司概况
公司名称：
康方生物
所属市场：
SEHK
上市日期：
--
主营业务：
康方生物科技（开曼）有限公司是一家主要从事生物产品研发的投资控股公司。该公司专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。该公司的主要产品包括AK104、AK105、AK112及AK109。该公司于中国市场及海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":40.65,"timestamp":1721981300033,"preClose":38.95,"halted":0,"volume":2253340,"delay":0,"floatShares":865857176,"shares":865857176,"eps":2.5991364,"marketStatus":"休市中","marketStatusCode":7,"change":1.7,"latestTime":"07-26 16:08:20","open":39.8,"high":40.8,"low":39.4,"amount":90766938,"amplitude":0.035944,"askPrice":40.7,"askSize":24000,"bidPrice":40.65,"bidSize":13000,"shortable":3,"etf":0,"ttmEps":2.59771950676066,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"listingDate":1587657600000,"adjPreClose":38.95,"openAndCloseTimeList":[[1721957400000,1721966400000],[1721970000000,1721980800000]],"volumeRatio":0.792688525303616,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2454369024","title":"康方生物午后涨超3% 此前获华福证券给予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2454369024","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454369024?lang=zh_cn&edition=full","pubTime":"2024-07-26 13:07","pubTimestamp":1721970455,"startTime":"0","endTime":"0","summary":"康方生物（09926）午后上涨3.08%，现报40.15港元，成交额4211.87万港元。\n 此前，华福证券发布研究报告称，预计康方生物（09926）2024-2026年营业收入分别为25.7、39.8、61.5亿元。根据DCF估值，按WACC为12.32%，永续增长率为3%，测算公司合理股价为55.85港元，合理市值为483.6亿港元，首次覆盖，给予“买入”评级。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-26/doc-incfmtue2088631.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-26/doc-incfmtue2088631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["09926"],"gpt_icon":0},{"id":"2454363379","title":"港股异动 | 康方生物(09926)现涨超3% 机构称AK112出海成功确定性逐步提升 公司当前市值被严重低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2454363379","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454363379?lang=zh_cn&edition=full","pubTime":"2024-07-26 11:51","pubTimestamp":1721965900,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物现涨超3%，截至发稿，涨3.08%，报40.15港元，成交额4075.42万港元。德邦证券指出，2024年5月AK112获批上市，用于治疗EGFR-TKI进展的局部晚期或转移性nsqNSCLC，总审评用时不到10个月，超出预期。叠加与K药头对头数据的读出，使得AK112的商业化前景及海外成功的确定性大大提升。AK112的出海成功确定性逐步提升，海外价值未被充分认知，我们认为公司有潜力进化为具有国际竞争力的中国一流的biopharma药企，当前市值被严重低估。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1155967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0348784397.USD","LU1720050803.USD","LU1794554557.SGD","LU2488822045.USD","YANG","HSTECH","IE00B543WZ88.USD","BK1574","BK1161","LU0348783233.USD","LU0417516571.SGD","IE00BPRC5H50.USD","09926","HSCEI"],"gpt_icon":1},{"id":"2453770763","title":"康方生物委任首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2453770763","media":"北京商报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453770763?lang=zh_cn&edition=full","pubTime":"2024-07-22 18:53","pubTimestamp":1721645618,"startTime":"0","endTime":"0","summary":"7月22日，康方生物发布公告称，BingC.WANG博士（王秉中）已获委任为公司首席财务官。王秉中在生物制药领域拥有多年全球化战略投资、公司融资、财务管理及企业发展经验。在加入康方之前，王秉中于一家致力于基于基因编辑平台开发CAR—T细胞和肿瘤免疫疗法的法国生物制药公司Cellectis担任首席财务官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407223136958658.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407223136958658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BPRC5H50.USD","09926","IE00B5MMRT66.SGD","LU2488822045.USD","LU1720050803.USD","BK1574","IE00B543WZ88.USD","LU0417516571.SGD","LU1794554557.SGD","LU0348784397.USD","LU0348783233.USD","BK1161"],"gpt_icon":0},{"id":"2453386297","title":"《大行》中金最新海外中资股策略首选组合(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2453386297","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453386297?lang=zh_cn&edition=full","pubTime":"2024-07-22 12:35","pubTimestamp":1721622900,"startTime":"0","endTime":"0","summary":"沽空资料截至 2024-07-22 12:25。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180503142123924_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180503142123924_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1365278/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02020","00883","00639","00285","00700","BK1528","BK1610","00288","BK1594","02018","09992","09926","XIACY","ANPDY","SG9999001051.SGD","LU0359202008.SGD","02601","02367","80700","80883","03668","00941","HK0000306685.HKD","HK0000306701.USD","IE00B543WZ88.USD","LU1813983027.USD","09896","IE00B5MMRT66.SGD","BK1095","LU0181495838.USD","00921","LU0054237671.USD","81024","IE00B0169L03.USD","LU0516423174.USD","03606","81810","LU0594300419.USD","82020","01024","LU0080751232.USD","LU1794554557.SGD","02313","01810","BK1512","LU0594300179.USD","02285","00780","LU0029875118.USD","00968"],"gpt_icon":1},{"id":"2453844867","title":"康方生物(09926)：王秉中博士获委任为公司新任领导","url":"https://stock-news.laohu8.com/highlight/detail?id=2453844867","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453844867?lang=zh_cn&edition=full","pubTime":"2024-07-22 09:51","pubTimestamp":1721613105,"startTime":"0","endTime":"0","summary":"快讯摘要康方生物7月22日公告，BingC.WANG博士(王秉中)新任公司职位，引发市场关注。快讯正文【康方生物宣布任命BingC.WANG博士为新任公司领导】康方生物于2024年7月22日宣布，BingC.WANG博士(王秉中)已正式被任命为公司新任领导。这一人事变动预计将对公司的战略方向和管理层结构产生重要影响，值得二级市场投资者密切关注。下载和讯APP查看快讯，体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407221130249edd9bd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407221130249edd9bd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BPRC5H50.USD","LU1794554557.SGD","LU2488822045.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1720050803.USD","LU0348784397.USD","09926","BK1574","LU0417516571.SGD","BK1161"],"gpt_icon":0},{"id":"2453220261","title":"康方生物(09926)：王秉中获委任为公司首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2453220261","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453220261?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:26","pubTimestamp":1721608011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物(09926)于2024年7月22日宣布，Bing C . WANG博士(王秉中)已获委任为公司首席财务官。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348783233.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1794554557.SGD","LU0417516571.SGD","IE00BPRC5H50.USD","BK1161","LU1720050803.USD","LU0348784397.USD","LU2488822045.USD","BK1574","09926"],"gpt_icon":0},{"id":"2453202828","title":"康方生物(09926.HK)委任首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2453202828","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453202828?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:24","pubTimestamp":1721607840,"startTime":"0","endTime":"0","summary":"康方生物(09926.HK) 公布，王秉中(Bing C. WANG)已获委任为首席财务官。(jl/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-19 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1365121/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0348783233.USD","LU1720050803.USD","BK1574","IE00B543WZ88.USD","09926","LU0348784397.USD","LU0417516571.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2452423260","title":"中欧医疗健康股票仓位升至三年最高 葛兰二季度十大重仓股出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2452423260","media":"澎湃新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452423260?lang=zh_cn&edition=full","pubTime":"2024-07-19 17:12","pubTimestamp":1721380320,"startTime":"0","endTime":"0","summary":" 中欧医疗健康股票仓位升至三年最高水平！7月19日，中欧基金葛兰在管的3只公募基金披露2024年二季报，其持仓情况也随之浮出水面。 截至2024年二季度末，葛兰在管公募基金规模约为407.65亿元，相较于一季度末时的458.74亿元，下降11.14%。 股票仓位方面，葛兰在2024年二季度小幅度提升了中欧医疗健康的股票仓位，由原本的92.79%升至93.73%，这已是该基金三年来最高水平；另外2只基金的股票仓位则小幅度下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-07-19/doc-inceshny5448585.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-07-19/doc-inceshny5448585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999001093.SGD","000423","300347","300760","002475","LU0456827905.SGD","BK1219","LU0871576103.HKD","09926","02273","000568","IE00BMPRXN33.USD","LU0327786744.USD","002371","BK0236","300308","600519","605333","LU1781817850.SGD","300759","603259","LU2488822045.USD","300502","LU1880383366.USD","600276","300015","LU2148510915.USD","600085","BK0187","LU0531971595.HKD","LU0577902371.SGD","LU0880133367.SGD","300274","BK0028","603456","600436","600938","HK0000306701.USD","LU0359202008.SGD","LU0516423091.SGD","LU1051769294.HKD","BK0171","02269","LU0320764599.SGD","000921","000999","601127","HK0000306685.HKD","LU0594300179.USD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2452956994","title":"南向资金7月18日净买入康方生物49.10万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452956994","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452956994?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:31","pubTimestamp":1721352700,"startTime":"0","endTime":"0","summary":"7月18日, 南向资金增持康方生物49.10万股，连续7日增持。截止当日收盘，港股通共持有康方生物31611.36万股，占流通股36.50%。康方生物近5个交易日上涨5.09%，港股通累计增持232.47万股；近20个交易日上涨9.08%，港股通累计增持199.55万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190943529f68749f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190943529f68749f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BPRC5H50.USD","BK1161","LU0348784397.USD","IE00B543WZ88.USD","LU0417516571.SGD","LU1720050803.USD","BK1574","09926","LU2488822045.USD","LU0348783233.USD","LU1794554557.SGD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2452717979","title":"南向资金7月16日净买入康方生物8.69万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452717979","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452717979?lang=zh_cn&edition=full","pubTime":"2024-07-17 09:31","pubTimestamp":1721179891,"startTime":"0","endTime":"0","summary":"7月16日, 南向资金增持康方生物8.69万股，连续5日增持。截止当日收盘，港股通共持有康方生物31524.39万股，占流通股36.40%。港股通增持金额前五个股分别为工商银行、招商银行、小米集团-W、安踏体育、建设银行。康方生物近5个交易日上涨5.23%，港股通累计增持241.68万股；近20个交易日下跌3.80%，港股通累计增持139.28万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071709470295cb8ef5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071709470295cb8ef5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BPRC5H50.USD","LU1794554557.SGD","LU2488822045.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1720050803.USD","LU0348784397.USD","09926","BK1574","LU0417516571.SGD","BK1161"],"gpt_icon":0},{"id":"2451935175","title":"康方生物早盘涨近4% 华福证券首次覆盖给予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2451935175","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451935175?lang=zh_cn&edition=full","pubTime":"2024-07-16 11:34","pubTimestamp":1721100871,"startTime":"0","endTime":"0","summary":"康方生物早盘上涨3.50%，现报39.90港元，成交额1.80亿港元。 近日，华福证券发布研究报告称，预计康方生物）2024-2026年营业收入分别为25.7、39.8、61.5亿元。根据DCF估值，按WACC为12.32%，永续增长率为3%，测算公司合理股价为55.85港元，合理市值为483.6亿港元，首次覆盖，给予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-16/doc-incehync8268441.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-16/doc-incehync8268441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["09926"],"gpt_icon":0},{"id":"2451386469","title":"港股异动 | 康方生物(09926)涨超5% 卡度尼利一线治疗晚期宫颈癌III期研究达PFS和OS双主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2451386469","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451386469?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:58","pubTimestamp":1721098724,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物涨超5%，截至发稿，涨5.19%，报40.55港元，成交额1.68亿港元。消息面上，康方生物今日宣布，公司独立自主研发的PD-1/CTLA-4双特异性抗体卡度尼利（开坦尼）联合含铂化疗+/-贝伐珠单抗对比安慰剂联合含铂化疗＋/-贝伐珠单抗用于一线治疗持续、复发或转移性宫颈癌的III期临床研究在期中分析中达到总生存期主要研究终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4211","LU2488822045.USD","HSTECH","YANG","LU0348784397.USD","III","IE00BPRC5H50.USD","HSCEI","BK4134","LU1720050803.USD","LU1794554557.SGD","IE00B543WZ88.USD","07226","09926","IE00B5MMRT66.SGD","LU0348783233.USD","BK1161","BK1574","LU0417516571.SGD","PFS","BK4195"],"gpt_icon":0},{"id":"2451544938","title":"康方生物(09926)上涨5.06%，报40.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451544938","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451544938?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:48","pubTimestamp":1721098109,"startTime":"0","endTime":"0","summary":"7月16日，康方生物盘中上涨5.06%，截至10:48，报40.5元/股，成交1.54亿元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司，其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2023年年报，康方生物营业总收入45.26亿元、净利润20.28亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/16104841589106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0348783233.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1794554557.SGD","LU0417516571.SGD","IE00BPRC5H50.USD","BK1161","LU1720050803.USD","LU0348784397.USD","LU2488822045.USD","BK1574","09926"],"gpt_icon":0},{"id":"2451406980","title":"康方生物盘中异动 早盘急速拉升5.06%报40.501港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451406980","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451406980?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:48","pubTimestamp":1721098105,"startTime":"0","endTime":"0","summary":"2024年07月16日早盘10时48分，康方生物股票出现异动，股价大幅上涨5.06%。截至发稿，该股报40.501港元/股，成交量387.3万股，换手率0.45%，振幅3.76%。资金方面，该股资金流入7803.77万港元，流出4592.34万港元。康方生物股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，盛禾生物-B、康方生物、亚盛医药-B涨幅较大，振幅较大的相关个股有宜明昂科-B、圣诺医药-B、来凯医药-B，振幅分别为16.14%、14.51%、12.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240716104826aef9d9db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240716104826aef9d9db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0348783233.USD","LU1794554557.SGD","LU1720050803.USD","09926","IE00B5MMRT66.SGD","LU2488822045.USD","BK1574","LU0348784397.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0417516571.SGD"],"gpt_icon":0},{"id":"2451938927","title":"康方生物(09926)股价上升5.058%，现价港币$40.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2451938927","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451938927?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:48","pubTimestamp":1721098080,"startTime":"0","endTime":"0","summary":"[上升股]康方生物(09926) 股价在上午10:48比前收市价上升5.058%，现股价为港币$40.5。至目前为止，今日最高价为$40.5，而最低价为$39.05。总成交量为385.1万股，总成交金额为港币$1.536亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407161159/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","IE00B5MMRT66.SGD","LU1720050803.USD","LU1794554557.SGD","LU2488822045.USD","BK1574","IE00B543WZ88.USD","LU0417516571.SGD","09926","IE00BPRC5H50.USD","LU0348783233.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2451998143","title":"《大行》野村降康方生物(09926.HK)目标价至46.04元 下调今明两年收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2451998143","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451998143?lang=zh_cn&edition=full","pubTime":"2024-07-16 09:23","pubTimestamp":1721092980,"startTime":"0","endTime":"0","summary":"野村发表研究报告指，康方生物获维持“买入”评级，但目标价由52.8元下调至46.04元。该行考虑到持续的不利政策影响、凯得宁单抗或将在最新的国家医保目录中降价，令销售预测下调、依沃西单抗疗效数据具争议及其他候选药物的销售预期下降，因此将集团2024及25财年的收入预测分别下调2.9%和25.2%。该行表示，由于最近凯得宁单抗的定价调整，将公司2024财年的亏损预测削减39.5%，但由于国家医保目录谈判可能导致价格下调，将2025财年的盈利预测下调57.8%。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1363855/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09926"],"gpt_icon":0},{"id":"2451668498","title":"南向资金7月12日净买入康方生物77.05万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2451668498","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451668498?lang=zh_cn&edition=full","pubTime":"2024-07-15 09:31","pubTimestamp":1721007099,"startTime":"0","endTime":"0","summary":"7月12日, 南向资金增持康方生物77.05万股，连续3日增持。截止当日收盘，港股通共持有康方生物31455.94万股，占流通股36.32%。港股通增持金额前五个股分别为建设银行、中国移动、中国联通、碧桂园服务、名创优品。康方生物近5个交易日上涨3.34%，港股通累计增持118.33万股；近20个交易日上涨0.25%，港股通累计增持142.93万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407150944469f4bb70d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407150944469f4bb70d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B543WZ88.USD","LU0348784397.USD","LU0417516571.SGD","LU2488822045.USD","BK1161","LU0348783233.USD","IE00BPRC5H50.USD","09926","LU1720050803.USD","BK1574","IE00B5MMRT66.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2451966659","title":"康方公司核心产品的估值预估及其在国内市场的销售额预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2451966659","media":"调研三人行","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451966659?lang=zh_cn&edition=full","pubTime":"2024-07-15 07:58","pubTimestamp":1721001539,"startTime":"0","endTime":"0","summary":"康方生物的PD-1双抗产品之所以能在全球范围内取得巨大成功并成为抗肿瘤药物基石，主要有两个关键因素。康方公司核心产品的估值预估及其在国内市场的销售额预测如何？我们在评估康方公司时主要考虑了其两个核心产品。目前正在进行六项三期临床试验，包括胃癌、宫颈癌、肝癌及肺癌等，预计其中部分适应症可贡献超过10亿的销售量。考虑到当前的风险溢价水平较高，康方公司的股价处于底部状态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407150757349681c7f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407150757349681c7f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348783233.USD","LU1720050803.USD","BK1574","IE00B543WZ88.USD","09926","LU0348784397.USD","LU0417516571.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2450237327","title":"港股异动 | 康方生物(09926)现涨近5% 依沃西单抗最大的不确定性已落地 有望后续在海外上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2450237327","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450237327?lang=zh_cn&edition=full","pubTime":"2024-07-12 14:07","pubTimestamp":1720764461,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物现涨近5%，截至发稿，涨4.83%，报40.15港元，成交额2.24亿港元。该行指出，治疗肺癌 EGFR TKI 耐药适应症已获批，有重要临床意义；阳性结果标志着 AK112 研发成功率中最大的不确定性已落地。国联证券发研报指，康方生物为国内首个国产双抗商业化落地的企业，布局肿瘤类双抗、自免和降脂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00B543WZ88.USD","YANG","LU0348784397.USD","HSCEI","LU0417516571.SGD","BK1161","HSTECH","LU0348783233.USD","LU2488822045.USD","IE00BPRC5H50.USD","09926","07226","LU1720050803.USD","BK1574","IE00B5MMRT66.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2450326034","title":"康方生物盘中异动 早盘股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450326034","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450326034?lang=zh_cn&edition=full","pubTime":"2024-07-12 11:20","pubTimestamp":1720754444,"startTime":"0","endTime":"0","summary":"2024年07月12日早盘11时20分，康方生物股票出现波动，股价快速上涨5.09%。康方生物股票所在的生物技术行业中，整体涨幅为1.24%。消息层面，截至11时20分，康方生物股票正面舆情新闻比例37.5%。《华福证券：首予康方生物“买入”评级 目标价55.85港元》资讯为影响康方生物的重要信息。该信息摘要如下：华福证券发布研究报告称，预计康方生物2024-2026年营业收入分别为25.7、39.8、61.5亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121120459681c414&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121120459681c414&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348783233.USD","LU1720050803.USD","BK1574","IE00B543WZ88.USD","09926","LU0348784397.USD","LU0417516571.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0087},{"period":"3month","weight":-0.1653},{"period":"6month","weight":-0.0287},{"period":"1year","weight":-0.0061},{"period":"ytd","weight":-0.1239}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0591},{"period":"3month","weight":-0.0357},{"period":"6month","weight":0.067},{"period":"1year","weight":-0.1333},{"period":"ytd","weight":-0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家主要从事生物产品研发的投资控股公司。该公司专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。该公司的主要产品包括AK104、AK105、AK112及AK109。该公司于中国市场及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.000127},{"month":2,"riseRate":0.25,"avgChangeRate":-0.01324},{"month":3,"riseRate":0.25,"avgChangeRate":-0.055315},{"month":4,"riseRate":0.75,"avgChangeRate":0.01855},{"month":5,"riseRate":0.4,"avgChangeRate":0.001922},{"month":6,"riseRate":0.6,"avgChangeRate":0.140431},{"month":7,"riseRate":0.4,"avgChangeRate":-0.039571},{"month":8,"riseRate":0.25,"avgChangeRate":-0.053599},{"month":9,"riseRate":0.5,"avgChangeRate":-0.021692},{"month":10,"riseRate":0.75,"avgChangeRate":0.139401},{"month":11,"riseRate":1,"avgChangeRate":0.091362},{"month":12,"riseRate":0.5,"avgChangeRate":0.104965}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}